Plerixafor-d4 – 1 mg

Brand:
Cayman
CAS:
1246819-87-3
Storage:
-20
UN-No:
Non-Hazardous - /

Plerixafor-d4 is intended for use as an internal standard for the quantification of plerixafor (Item No. 10011332) by GC- or LC-MS. Plerixafor is a partial antagonist of chemokine receptor 4 (CXCR4) with IC50 values ranging from 0.02 to 0.13 µg/ml for inhibiting calcium flux in peripheral blood mononuclear cells (PBMCs), various types of T cells, and mouse lymphocytic leukemia cells.{42569} It is selective for CXCR4 over CXCR1-3 and CXCR5-9 (IC50s = >25 µg/ml). Plerixafor decreases infectious virus content in the supernatant of Jurkat cells chronically infected with HIV-1(IIIB) (EC50 = ~0.02 µg/ml).{16446} It rapidly mobilizes murine and human hematopoietic stem and murine long-term repopulating cells for transplantation alone and, with a synergistic effect, when used in combination with G-CSF.{15446} Plerixafor also increases T cell trafficking in mouse blood, spleen, and central nervous system.{16445,16447} Plerixafor (1.25 mg/kg twice per day) decreases the number of 4T1 murine mammary carcinoma cells in the lung in a mouse model of lung metastasis.{15450}  

 

Available on backorder

SKU: 26490 - 1 mg Category:

Description

An internal standard for the quantification of plerixafor by GC- or LC-MS


Formal name: 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene-d4

Synonyms: 

Molecular weight: 506.8

CAS: 1246819-87-3

Purity: ≥99% deuterated forms (d1-d4)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS